Bispecific antibodies targeting EGFR and HER2
US12054550B2 · kind B2 · utility
0Cited by
6References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 28, 2017 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Apr 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.